Elan L. Guterman

Elan L. Guterman

Auto-generated profile, based on publicly available information

Elan L. Guterman

Department of Neurology, University of California, San Francisco

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
EGElan L. Guterman
Elan L. Guterman
IAI. Elaine Allen
I. Elaine Allen
SJS. Andrew Josephson
S. Andrew Josephson
JMJennifer J. Merrilees
Jennifer J. Merrilees
SDSarah Dulaney
Sarah Dulaney
KPKatherine L. Possin
Katherine L. Possin
Current attempts to gauge the acute care needs of patients with dementia have focused on health-related concerns and the financial burden of emergency department (ED) and hospital use.1-10 Caregivers of patients with dementia have received considerably less attention despite their crucial role in health maintenance and resource use in this patient population.11-13

1 May 2021 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
EGElan L. Guterman
Elan L. Guterman
JBJohn P. Betjemann
John P. Betjemann
AAAlex Aimetti
Alex Aimetti
JLJustin W. Li
Justin W. Li
ZWZheng Wang
Zheng Wang
ASAdam Strzelczyk
Adam Strzelczyk
Status epilepticus (SE) is a common and life-threatening disorder, with an estimated annual incidence between 12 and 61 cases per 100 000 person-years and annual.1-7 Despite the high frequency and associated mortality, there are limited data detailing health care use and inpatient costs associated with SE-related hospitalizations and characterizing the variance of clinical outcomes and costs as a function of disease severity and medication refractoriness.8

17 September 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
EGElan L. Guterman
Elan L. Guterman
JSJoseph K. Sanford
Joseph K. Sanford
JBJohn P. Betjemann
John P. Betjemann
LZLi Zhang
Li Zhang
JBJames F. Burke
James F. Burke
KSKarl A. Sporer
Karl A. Sporer
Objective To examine the use of benzodiazepines and the association between low benzodiazepine dose, breakthrough seizures, and respiratory support in patients with status epilepticus. Methods In this cross-sectional analysis of adult patients with status epilepticus treated by an emergency medical services agency from 2013 to 2018, the primary outcome was treatment with a second benzodiazepine dose, an indicator for breakthrough seizure. The secondary outcome was receiving respiratory support. Midazolam was the only benzodiazepine administered. Results Among 2,494 patients with status epilepticus, mean age was 54.0 years and 1,146 (46%) were female. There were 1,537 patients given midazolam at any dose, yielding an administration rate of 62%. No patients received a dose and route consistent with national guidelines. Rescue therapy with a second midazolam dose was required in 282 (18%) patients. Higher midazolam doses were associated with lower odds of rescue therapy (odds ratio [OR], 0.8; 95% confidence interval [CI], 0.7–0.9) and were not associated with increased respiratory support. If anything, higher doses of midazolam were associated with decreased need for respiratory support after adjustment (OR, 0.9; 95% CI, 0.8–1.0). Conclusions An overwhelming majority of patients with status epilepticus did not receive evidence-based benzodiazepine treatment. Higher midazolam doses were associated with reduced use of rescue therapy and there was no evidence of respiratory harm, suggesting that benzodiazepines are withheld without clinical benefit. Classification of evidence This study provides Class III evidence that for patients with status epilepticus, higher doses of midazolam led to a reduced use of rescue therapy without an increased need for ventilatory support.

7 June 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
EGElan L. Guterman
Elan L. Guterman
BYBrian Yurgionas
Brian Yurgionas
ANAlexandra B. Nelson
Alexandra B. Nelson
A 38-year-old man presented to our clinic for evaluation of increasingly frequent spells of gait instability, diplopia, vertigo, and dysarthria. These spells began at 12 years of age. Initially, he experienced isolated periods of vertigo without accompanying symptoms. He told no family or friends of his problem at the time. Two years later, the symptoms progressed, manifesting as semistereotyped episodes characterized by a shock-like sensation radiating from his neck down his back followed by binocular diplopia, vertigo, gait instability, mental clouding, and nausea lasting 2–8 hours. Later, he experienced dysarthria during spells. Interictally, he returned to his baseline except for a persistent mild diplopia.

16 November 2021 in JAMA
Verified
Journal Article
Open access
PDF file
EGElan L. Guterman
Elan L. Guterman
JBJames F. Burke
James F. Burke
KSKarl A. Sporer
Karl A. Sporer
The American Epilepsy Society guideline recommends that paramedics use midazolam (10 mg intramuscularly), lorazepam (4 mg intravenously), or diazepam (6-10 mg intravenously) as first-line treatment for status epilepticus.1 Small cohort studies suggest that patients are frequently undertreated, but this has not been examined broadly across the United States.2

11 June 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
NRNicole Rosendale
Nicole Rosendale
EGElan L. Guterman
Elan L. Guterman
JBJohn P. Betjemann
John P. Betjemann
SJS. Andrew Josephson
S. Andrew Josephson
VDVanja C. Douglas
Vanja C. Douglas
Objective To characterize the most common neurologic diagnoses leading to hospitalization for homeless compared to housed individuals and to assess whether homelessness is an independent risk factor for 30-day readmission after an admission for a neurologic illness. Methods We performed a retrospective serial cross-sectional study using data from the Healthcare Cost and Utilization Project California State Inpatient Database from 2006 to 2011. Adult patients with a primary neurologic discharge diagnosis were included. The primary outcome was 30-day readmission. We used multilevel logistic regression to examine the association between homelessness and readmission after adjustment for patient factors. Results We identified 1,082,347 patients with a neurologic primary diagnosis. The rate of homelessness was 0.37%. The most common indications for hospitalization among homeless patients were seizure and traumatic brain injury, both of which were more common in the homeless compared to housed population (19.3% vs 8.1% and 31.9% vs 9.2%, respectively, p < 0.001). A multilevel mixed-effects model controlling for patient age, sex, race, insurance type, comorbid conditions, and clustering on the hospital level found that homelessness was associated with increased 30-day readmission (odds ratio 1.5, 95% confidence interval 1.4–1.6, p < 0.001). This association persisted after this analysis was repeated within specific diagnoses (patients with epilepsy, trauma, encephalopathy, and neuromuscular disease). Conclusion The most common neurologic reasons for admission among homeless patients are seizure and traumatic brain injury; these patients are at high risk for readmission. Future interventions should target the drivers of readmissions in this vulnerable population.